Article

Impact of homologous recombination deficiency on CDK4/6 inhibitor sensitivity in HR+/HER2-breast cancer

2025-08-13

Abstract excerpt

<title>Abstract</title> <p>While the combination of endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i) improves progression-free survival (PFS) in HR+/HER2- metastatic breast cancer, resistance remains a major challenge. <italic>BRCA2</italic> pathogenic variants have been linked to reduced PFS, potentially due to co-deletion of the neighboring <italic>RB1</italic> gene on chromosome 13q. As RB1 is a key targ...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 17cd6005-1d6e-58d7-93e0-6cf4b056ccdb
DOI: 10.21203/rs.3.rs-7253927/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Impact of homologous recombination deficiency on CDK4/6 inhibitor sensitivity in HR+/HER2-breast cancerDOI 10.21203/rs.3.rs-7253927/v1Read

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancerSemantic proximity Read

Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancerSemantic proximity Read

Efficacy and Mechanism of the Combination of PARP and CDK4/6 Inhibitors in the Treatment of Triple-negative Breast CancerSemantic proximity Read

Therapeutic targeting and patient selection for cancers with homologous recombination defects.Semantic proximity Read

Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies.Semantic proximity Read

Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.Semantic proximity Read

Pan-cancer Analysis of Homologous Recombination Deficiency in Cell LinesSemantic proximity Read

The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast CancerSemantic proximity Read

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast CancersSemantic proximity Read

Clinical approaches to overcome PARP inhibitor resistanceSemantic proximity Read

Whole Genome Analysis Identifies Homologous Recombination Deficiency in Cancers with BRCA1/2 Wild-Type and BRCA1/2 Structural VariantsSemantic proximity Read

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancerSemantic proximity Read